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Abstract
Despite evidence that antitumor immunity can be protective against renal cell carcinoma (RCC), few patients respond
objectively to immunotherapy and the disease is fatal once metastases develop. We asked to what extent combinatorial
immunotherapy with Adenovirus-encoded murine TNF-related apoptosis-inducing ligand (Ad5mTRAIL) plus CpG
oligonucleotide, given at the primary tumor site, would prove efficacious against metastatic murine RCC. To quantitate
primary renal and metastatic tumor growth in mice, we developed a luciferase-expressing Renca cell line, and monitored
tumor burdens via bioluminescent imaging. Orthotopic tumor challenge gave rise to aggressive primary tumors and lung
metastases that were detectable by day 7. Intra-renal administration of Ad5mTRAIL+CpG on day 7 led to an influx of effector
phenotype CD4 and CD8 T cells into the kidney by day 12 and regression of established primary renal tumors. Intra-renal
immunotherapy also led to systemic immune responses characterized by splenomegaly, elevated serum IgG levels,
increased CD4 and CD8 T cell infiltration into the lungs, and elimination of metastatic lung tumors. Tumor regression was
primarily dependent upon CD8 T cells and resulted in prolonged survival of treated mice. Thus, local administration of
Ad5mTRAIL+CpG at the primary tumor site can initiate CD8-dependent systemic immunity that is sufficient to cause
regression of metastatic lung tumors. A similar approach may prove beneficial for patients with metastatic RCC.
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Introduction
Patients with metastatic renal cell carcinoma (RCC) face a
dismal prognosis and have limited therapeutic options. Median
survival in a recent cohort was only 1.5 years with fewer than 10%
of patients surviving to five years [1]. Immunotherapy with high
dose IL-2 has a 20% response rate, including a 5–10% complete
response rate, but is poorly tolerated and has significant side effects
that limit its use to specialized centers with highly selected patients
[2,3,4,5]. While newer treatments, such as the multikinase
inhibitors sunitinib and sorafenib, show small improvements in
survival, complete responses are rare with these agents [6]. A
treatment that could deliver durable, complete responses without
the rigors of high dose IL-2 would be a major advance for patients
with this deadly disease.
TNF-related apoptosis-inducing ligand (TRAIL) is a member of
the Tumor Necrosis Factor family that has the ability to induce
apoptosis in malignant cells, while largely sparing untransformed,
normal tissues [7,8,9,10]. TRAIL ligation of cognate death-
inducing receptors (TRAIL-R1 and TRAIL-R2 in humans, DR5
in mice) [11] triggers apoptotic death in tumor cells, thereby
increasing the amount of tumor cell antigen potentially available
for uptake and processing by local antigen-presenting cells (APCs)
[10]. Typically, phagocytosis of apoptotic bodies by APCs results
in immune tolerance rather than protective immunity [12].
Therefore, to initiate protective anti-tumor immunity, APCs
processing TRAIL-generated apoptotic tumor cells need to receive
a separate stimulatory signal. CpG oligodeoxynucleotides contain
unmethylated CG motifs that bind to toll-like receptor 9 (TLR9),
activating APCs and increasing their MHC and co-stimulatory
molecule expression, and cytokine production [13,14]. As a result,
co-administration of CpG with TRAIL provides the stimulatory
signal APCs need to initiate protective immunity to tumor-derived
antigens. Both TRAIL and CpG have shown minimal toxicity in
Phase I clinical trials, making them excellent candidates for
antitumor immunotherapies [9,15].
We showed previously that intratumoral co-administration of a
replication-deficient adenovirus encoding murine TRAIL (Ad5m-
TRAIL) plus CpG1826 resulted in enhanced CD8 T cell-mediated
antitumor immunity and clearance of localized subcutaneous (s.c.)
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administration of Ad5mTRAIL+CpG led to a systemic memory
CD8 T cell response that protected mice from subsequent Renca
re-challenge. In contrast, CD4 T cells were largely suppressive,
and impaired both Ad5mTRAIL+CpG efficacy and CD8 T cell
proliferation. The induction of a humoral immune response to
intratumoral Ad5mTRAIL+CpG therapy was not investigated.
Therefore, despite its encouraging results, our prior study had
several important limitations. First, as the numbers and types of
APCs differ substantially from one anatomic location to another,
demonstrated Ad5mTRAIL+CpG efficacy in a localized s.c.
model of RCC provided little evidence that the therapy would
be effective in a more physiologically relevant orthotopic RCC
model, where CpG would have to activate limited numbers of
renal APCs. Furthermore, as the primary clinical application of
immunotherapy is in the treatment of advanced cancers that have
already disseminated, it was important for us to evaluate the
efficacy of Ad5mTRAIL+CpG in a pre-clinical model of
metastatic RCC.
Recent evidence in a small number of clinical cases suggests that
T cell-mediated eradication of metastatic RCC in patients may be
feasible [17,18,19]. To determine the extent to which local
administration of Ad5mTRAIL+CpG at the primary tumor site
would stimulate T cell-mediated eradication of metastatic RCC,
we developed a murine model based on intrarenal (IR) injections
of Renca tumor cells engineered to express Luciferase. Renca cells
injected IR develop into primary renal tumors that spontaneously
metastasize to the lungs [20,21,22]. Luciferase expression in tumor
cells allows for the quantitative analysis of primary and metastatic
tumor growth in live animals over time. As the lungs are one of the
primary metastatic sites in patients with advanced RCC [23], this
model provides a clinically relevant means of assessing the
immunotherapeutic efficacy of Ad5mTRAIL+CpG against met-
astatic RCC. We demonstrate here that Ad5mTRAIL+CpG,
given at the primary renal tumor site, leads to infiltration of tumor-
bearing kidneys by effector CD4 and CD8 T cells. It also leads to
increased infiltration of CD4 T cells and CD8 T cells into the
lungs. Elimination of both primary and metastatic tumors ensues
and is mediated primarily by CD8 T cells. In addition,
Ad5mTRAIL+CpG induces splenomegaly and a humoral re-
sponse characterized by increased serum levels of total IgG, anti-
adenoviral IgG, and anti-dsDNA without progression to autoim-
munity. These results demonstrate the feasibility of using a T cell-
stimulatory immunotherapy for the treatment of metastatic RCC,
and suggest that Ad5TRAIL+CpG as a therapeutic approach may
be an efficacious, yet well-tolerated option for patients with
advanced disease.
Methods
Mice/Ethics Statement
Female BALB/c mice (7–8 wk old) were purchased from the
National Cancer Institute or Harlan Laboratories. All animal
procedures were approved by the Institutional Animal Care and
Use Committee at The University of Iowa (ACURF #0912282).
Cell lines
The murine renal adenocarcinoma cell line, Renca, was
obtained from Dr. Robert Wiltrout (National Cancer Institute,
Frederick, MD), and was authenticated in 2010 by microsatellite
marker analysis (Research Animal Diagnostic Laboratory, Co-
lumbia, MO). Renca cells were maintained in Complete RPMI as
previously described [16]. Renca-Luc is a variant that stably
expresses firefly Luciferase; it was generated via retroviral
transduction as described [24,25]. Renca-Luc cells were main-
tained in Complete RPMI supplemented with 0.05 mg/ml
puromycin.
Tumor challenge
For IR tumor challenge, a skin incision was made on the left
flank, and 2610
5 Renca or Renca-Luc cells were injected through
the intact peritoneum into the left kidney. On d 7 following tumor
challenge, mice were re-injected in the same kidney with either
sterile PBS, or 10
9 pfu of replication-deficient Ad5mTRAIL that
encodes a membrane-bound version of full-length murine TRAIL
protein with or without 100 mg CpG1826 (Coley Pharmaceuticals,
Wellesley, MA), in a 100 ml volume. Mice were sacrificed between
d 21–25, when untreated renal tumors were palpable. In some
experiments, CD4
+ or CD8
+ cells were depleted in vivo via i.p.
injection of either 100 mg/mouse GK1.5 (CD4) or 53.6.72 (CD8)
antibodies given on d 4, 6, 7, 14, and 21. Depletion efficacy was
monitored by flow cytometric analysis of CD4 and CD8 staining
of spleen samples in test mice; depletion of both T cell populations
was found to be greater than 90% (data not shown). In some mice,
s.c. tumor challenges were performed by injecting 2610
5 Renca-
Luc cells into the right hind flank; s.c. tumors were allowed to
grow for 37 d, at which time bioluminescent imaging (BLI) was
performed on live mice and excised lungs from euthanized
animals.
Bioluminescent imaging (BLI)
BLI was done using an IVIS 200 (Caliper Life Sciences,
Hopkinton, MA) as described [24,25]. Briefly, 10 min prior to
imaging, mice were injected i.p. with 100 mlo fa1 5 mg/ml
solution of D-Luciferin (GoldBio.com, St. Louis, MO), then
anesthetized via inhalation of oxygenated isoflurane. Live mice
were imaged for 1 min. Excised organs were imaged separately
with a 5 min exposure. Photon flux (photons/second) was
calculated within a defined region of interest using Living Image
software (Version 2.5).
Flow cytometry
Tumors, lungs, and spleens were harvested, manually disrupted,
then digested for 15–30 min in HBSS containing 0.56 Wuensch
units/ml of Liberase Blendzyme 3 (Roche, Branford, CT) and
0.15 mg/ml DNAse I (Sigma, St. Louis, MO), and prepared as
described to generate single cell suspensions [26]. Cells were
stained with combinations of the following antibodies, and results
acquired using multi-parameter flow cytometry on a BD LSR II
(BD Biosciences, San Diego, CA) then analyzed with FlowJo
software. An expanded FS/SSC gate was used to encompass not
only resting and blasted lymphocytes, but larger DC and more
granular macrophages, as appropriate. Doublets were excluded by
standard FSC-A/FSC-W gating. Dead cells were excluded via
Hoechst positivity. For DC: CD11c-biotin, streptavidin-APC/
Cy7, CD11b-PE/Cy7, Gr1-APC, I-A
d-PE, CD4-FITC; for T
cells: CD3-PE, CD8-APC, CD4-PE/Cy7, CD44-biotin, strepta-
vidin APC/Cy7; for macrophages: CD11b-PE/Cy7, for B cells:
B220- A488; for NK cells: DX5-FITC. Antibodies were from
eBioscience (San Diego, CA) or BioLegend (San Diego, CA).
Histology and microscopy
Excised kidneys were fixed in 10% Neutral Buffered Formalin,
embedded in paraffin, sectioned at a thickness of 8 microns, then
stained with Hematoxylin and Eosin. Sample processing and
staining was performed by the University of Iowa Department of
Pathology Histology Core facility. Photomicrographs were taken
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objective and CellSens Dimension software (Olympus Corp,
Cedar Valley, PA). Images were processed using Preview v4.2
software (Apple Inc., Cupertino, CA).
ELISA analysis of total IgG, anti-adenoviral IgG, and anti-
dsDNA Ab
Mice (3–10 per indicated treatment group) were bled on d 12,
20, and 48 after IR Renca tumor challenge. Serum was obtained
by centrifugation and frozen until use. Total IgG was measured
using a Mouse IgG ELISA kit (Immunology Consultants
Laboratory, Newberg, OR) according to the manufacturer’s
specifications. Measurement of anti-adenoviral IgG [27] was
performed by coating a 96-well microtiter plate with 10
9
Ad5mTRAIL particles/well in 100 ml sodium bicarbonate over-
night at 4uC. Wells were then washed and blocked in 100 ml PBS
containing 3% BSA and 0.01% Tween-20. Afterwards, the plate
was incubated 2 h at RT with 100 ml diluted plasma or mouse
adenovirus IgG1. Wells were washed, 100 ml HRP-conjugated
goat anti-mouse IgG Fc was added and incubated 2 h at RT.
Wells were washed and 100 ml TMB peroxidase substrate was
added. The reaction was stopped by adding 100 ml1MH 2SO4,
and absorbance was measured at 450 nm. Anti-dsDNA IgG was
measured using a mouse anti-dsDNA ELISA Kit (Shibayagi Co.,
Japan) according to the manufacturer’s specifications.
Statistics
Statistical significance was determined as p,0.05 for specified
sets of data via unpaired student t-test with Welch’s correction for
unequal variances. Data were analyzed using Prism software
(GraphPad Software Inc., La Jolla, CA).
Results
Aggressive primary tumors and spontaneous lung
metastases form following IR injections of Renca tumor
cells
The Renca cell line is derived from a spontaneously arising
renal adenocarcinoma of BALB/c mice [28], and is widely used to
model RCC. In many studies, Renca cells are injected s.c. to
produce localized tumors or intravenously (i.v.) to produce
experimental lung metastases [29,30,31,32,33]. We had previously
shown that intratumoral administration of Ad5mTRAIL plus
CpG1826 could lead to the eradication of localized s.c. Renca
tumors in mice [16]. In the current study, we evaluated the
efficacy of an Ad5mTRAIL+CpG combinatorial immunotherapy
in a more physiologically relevant orthotopic Renca model, where
IR tumor challenge gives rise to spontaneous lung metastases
[20,22,34].
To verify that our previous s.c. tumor challenge route did, in
fact, produce only localized tumors without metastases, we
injected a firefly Luciferase-expressing Renca variant (Renca-
Luc) s.c. into BALB/c mice and allowed it to grow unchecked
through d 37. At this time, whole-body BLI was performed on live
tumor-challenged and tumor-free control mice (Fig. 1A and B).
Light flux values in the flank were significantly greater than the
background flux emitted by tumor-free control mice, indicating
positive tumor growth. However, no disseminated tumor growth
was evident. We then euthanized mice and excised the lungs to
permit a more sensitive evaluation via BLI. The lungs of s.c.
tumor-challenged mice had similar light emission to excised lungs
from tumor-free control mice, indicating an absence of tumor
growth in this site (Fig. 1C). Therefore, Renca cells injected s.c.
into the flank do not metastasize from the injection site, a finding
that is in agreement with a recent study by Westwood et al. [20].
We then proceeded to evaluate the ability of Ad5-
mTRAIL+CpG to eliminate metastatic lung tumor growth when
administered intra-renally (IR) at the site of established primary
kidney tumors. To characterize orthotopic renal tumor formation
in the absence of immunotherapy, parental Renca cells were
injected directly into the left kidney of each mouse, and tumor
growth was assessed via measurement of excised kidney weights on
d 23. Large renal masses were evident in challenged kidneys, while
contralateral kidneys remained grossly unaltered (Fig. 2A). Prima-
ry tumor growth was rapid, and resulted in histologically
detectable tumor formation as early as d 7 post-challenge; by d
14 normal architecture was lost in nearly the entire kidney, and
necrotic areas within renal tumors were observed by d 21 (arrows,
Fig. 2B).
In humans, advanced renal tumors metastasize to the lungs
[23]. To determine if lung metastases had developed in mice
challenged IR with Renca cells, we performed tracheal insuffla-
tions of lungs en bloc with India Ink. In all challenged mice, tumor
nodules were visible on the lung surface by d 21 that could be
easily counted (Figs. 2C and 2D), illustrating tumor cell
dissemination from the primary IR challenge site and metastatic
colonization of lungs. Manual enumeration of surface lung tumors
is a frequently performed technique, but this method has several
limitations. For example, it may underestimate the total tumor
burden per lung, as it cannot identify tumors that form deep
within the lung tissue. To complement our use of the parental
Renca line, we again used the Renca-Luc variant in the IR tumor
challenge of BALB/c mice. Examination of excised kidneys by
BLI confirmed the presence of tumor growth in 100% of injected
kidneys by d 7 post-challenge – a time when growing tumors were
not macroscopically visible (Fig. 2E). The BLI detection of IR
Renca-Luc tumor growth at d 7 also corresponded precisely with
histologic evaluations performed following parental Renca chal-
lenge (Fig. 2B). Of note, we were also able to detect Luciferase-
positive tumor cells in the excised lungs of mice at d 7 post-
challenge (Fig. 2F). Collectively, these data show that orthotopic
tumor challenge of BALB/c mice with Renca or Renca-Luc cells
leads to aggressive primary renal tumor outgrowth and the
formation of spontaneous lung metastases. As both primary renal
tumors and lung metastases are present by d 7 post-IR tumor
challenge with Renca cells, this system represents a clinically
relevant murine model for evaluating the efficacy of experimental
immunotherapies against primary renal and metastatic RCC. BLI
of luciferase-expressing tumor cells is beneficial as it permits
longitudinal analysis of total, body-wide tumor burdens in live
mice. However, since Luciferase may stimulate a certain degree of
immune recognition as a foreign protein, we continued to use both
Renca-Luc and parental Renca in the following experiments, as
each cell type presents unique advantages.
Local administration of Ad5mTRAIL+CpG
immunotherapy leads to regression of primary renal
tumors
One limitation of using s.c. tumor challenges to evaluate the
efficacy of experimental immunotherapies is that the frequency
and type of APCs differ widely throughout the body. For example,
s.c. injection of tumor cells and immunotherapuetics can recruit
and activate Langerhans cells [35,36], but this DC population is
not present in the kidney, and therapies that successfully stimulate
Langerhans cells may not equivalently stimulate kidney-resident
DC populations. To evaluate the efficacy of our combinatorial
Ad5mTRAIL+CpG immunotherapy in the IR model of meta-
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treated IR on d 7 with PBS or Ad5mTRAIL+CpG. Kidneys were
harvested at d 12 for staining and flow cytometric analysis to
determine the extent to which the therapy led to increased T cell
infiltration into tumor-bearing kidneys. Administration of Ad5-
mTRAIL+CpG led to striking increases in the percentage of T
cells in tumor-bearing kidneys (Fig. 3A). As shown, approximately
96% of gated CD8 T cells and 100% of gated CD4 T cells were
CD44
high/CD62L
low, reflecting differentiation to an effector
phenotype.
We next asked if the influx of effector T cells into the kidney
resulted in renal tumor regression. Mice were challenged IR with
parental Renca, then on d 7 were given an IR dose of PBS, CpG
alone, Ad5mTRAIL alone, or Ad5mTRAIL+CpG; or were left
untreated. On d 23, tumor-challenged kidneys were excised and
weighed to evaluate primary tumor growth. Three experimental
groups (PBS, CpG, Ad5mTRAIL) showed significantly increased
kidney weights as compared to tumor-free control kidneys (Fig. 3B;
* p,0.05 for a given experimental group vs tumor-free kidneys). In
contrast, kidneys from mice that received Ad5mTRAIL+CpG on
d 7 remained statistically unchanged in weight through d 23
(Ad5mTRAIL+CpG vs tumor-free, p=0.14). These data indicate
that tumors did not grow progressively in mice that received
Ad5mTRAIL+CpG on d 7, as they did in mice that received PBS,
CpG, or Ad5mTRAIL alone. We also found that IR administra-
tion of PBS on d 7 did not alter primary renal tumor outgrowth as
compared to mice that received no IR injections on d 7 (PBS vs no
Rx, p=0.734), suggesting that physical trauma associated with a
second IR injection did not alter the course of tumor outgrowth.
Histological evaluations of tumor-challenged kidneys revealed that
increased kidney weights were due to solid tumor growth and not
merely to an influx of inflammatory cells (Fig. 3C). Thus, only the
combination of Ad5mTRAIL+CpG was effective at controlling
renal tumor outgrowth.
Both CD4 and CD8 T cells can mediate tumor regression
[16,37], and the relative contribution of each lymphocyte
population may vary depending on the tumor model. To identify
the contributions of CD4 and CD8 T cells in protective antitumor
immunity that resulted from Ad5mTRAIL+CpG administration,
we performed IR tumor challenges with parental Renca cells as
above, then depleted mice of either CD4 or CD8 cells prior to
giving immunotherapy on d 7. Depletion of CD8 cells prior to
Figure 1. Renca s.c. tumor challenge produces only local tumor growth. (A) Renca-Luc cells were injected s.c. and whole-body
bioluminescent images were taken on d 37. Shown are 3 tumor-free controls and 3 tumor-bearing mice. (B) Total light flux values acquired via BLI on
d 37 for individual tumor-bearing mice (n=6). The mean background light flux for 8 tumor-free mice is also shown. Data are cumulative from 2
independent experiments. (C) Total light flux values for individual excised lungs taken from tumor-free or tumor-bearing mice, as indicated.
doi:10.1371/journal.pone.0031085.g001
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primary renal tumor size (Ad5mTRAIL+CpG vs Ad5-
mTRAIL+CpG – CD8, p=.002), indicating that in the absence
of CD8 cells, Ad5mTRAIL+CpG therapy was no longer effective
(Fig. 3B). Depletion of CD4 cells led to a slight increase in primary
renal tumor size as compared to non-depleted mice, but this
difference was not statistically significant (p=0.14). The latter
finding is in contrast to our previous results in the s.c. Renca
model, wherein CD4 depletion actually enhanced the efficacy of
Ad5mTRAIL+CpG therapy [16].
Both gross and histological examination of kidneys showed that
PBS-treated mice developed bulky renal tumors that obliterated
normal kidney structure and greatly increased the overall kidney
size (Fig. 3C). In contrast, kidneys from mice that received
Figure 2. Orthotopic injection of Renca tumor cells leads to aggressive primary tumors and spontaneous lung metastases. (A)
Parental Renca cells were injected IR, and weights of excised kidneys in grams (gm) were recorded on d 23. Representative data from .5
independent experiments are shown (n=5 mice per group). (B) H&E-stained sections from one normal tumor-free kidney, or tumor-bearing kidneys
harvested at the times indicated. Areas of dense purple staining indicate renal tumors. Scale bar=200 mm. (C, D) Quantitation of visible lung tumors
from 13 individual mice. Lungs were inflated with India Ink en bloc to allow visualization of white lung tumor nodules. (E, F) Total light flux values for
individual excised kidneys (E) and lungs (F) taken from mice on d 7 after IR Renca-Luc challenge or tumor-free (ctrl) mice.
doi:10.1371/journal.pone.0031085.g002
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injected IR, followed by PBS or Ad5mTRAIL (Ad5mTR) +CpG on d 7. Kidneys were excised on d 12 and analyzed by flow cytometry to assess T cell
infiltration. Dot plots show the percentages of live CD8
+ and CD4
+ T cells per kidney, as well as expression of CD44 and CD62L on the gated CD8
+ and
CD4
+ T cells. (B, C) Mice were challenged as in (A) and PBS, Ad5mTR and/or CpG was given on d 7. Tumor-challenged kidneys were excised and
weighed on d 23. CD4 and CD8 depletions were performed as described in Methods. Mean values from 4–10 mice per group, combined from 3
individual experiments, are shown. Asterisks indicate p,0.05 for that treatment group vs normal, tumor-free kidney weights. Statistical p values are
shown for PBS vs CpG, PBS vs Ad5mTR+CpG, Ad5mTR+CpG vs Ad5mTR+CpG with CD4 depletion, and Ad5mTR+CpG vs Ad5mTR+CpG with CD8
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and architecture. Small areas of renal tumor growth were still
present at this time, however, indicating that tumor eradication
was ongoing (arrows, Fig. 3C). Kidneys from mice that were
depleted of CD8 cells prior to Ad5mTRAIL+CpG therapy
resembled those of the PBS group; bulky renal tumors were
evident that consumed much of the normal kidney architecture
and increased the overall organ size. Collectively, the data in
Figure 3 demonstrate that local administration of Ad5-
mTRAIL+CpG immunotherapy initiated a CD8-dependent
immune response that was able to eradicate previously established
renal tumors in mice.
IR administration of Ad5mTRAIL+CpG generates systemic
immune responses
Immune-based therapies are promising treatment options for
metastatic cancer as both effector and memory T cells have the
potential to traffic systemically and provide protection against
disseminated tumor outgrowth. As a next step in evaluating the
potential utility of Ad5mTRAIL+CpG for metastatic RCC, we
examined mice for evidence of a systemic immune response
following local administration of therapy at the site of primary
renal tumor growth. Mice were challenged IR with parental
Renca cells, then treated IR with PBS, Ad5mTRAIL alone, CpG
alone, or Ad5mTRAIL+CpG on d 7. Mice receiving either
Ad5mTRAIL+CpG or CpG alone developed splenomegaly by d
12 (Fig. 4A; Ad5mTRAIL vs PBS, p=0.17; CpG vs Ad5-
mTRAIL+CpG, p=0.16), which remained through d 23–25 (data
not shown). To determine the extent to which different splenocyte
cell populations were specifically expanded in Ad5mTRAIL+
CpG-treated mice, we evaluated the frequencies of splenic B220
+
B cells, CD3
+CD4
+ T cells, CD3
+CD8
+ T cells, CD11c
high DC,
CD11b
+ macrophages, and DX5
+ NK cells. Splenic B cell, CD4 T
cell, and CD8 T cell frequencies actually decreased in Ad5-
mTRAIL+CpG-treated mice relative to PBS controls (Fig. 4B and
C). However, due to the increase in splenic cellularity, equal or
greater overall numbers of these cells were present in Ad5-
mTRAIL+CpG-treated mice (data not shown). The only cell
depletion. For PBS vs CpG alone or Ad5mTR alone p=0.11, for Ad5mTRAIL+CpG –CD8 vs Ad5mTRAIL+CpG –CD4 p=.14. (C) In addition, the excised
kidneys were processed for H&E staining. Areas of dense purple staining indicate renal tumors. Scale bars in upper panels=2.0 mm.
doi:10.1371/journal.pone.0031085.g003
Figure 4. IR administration of Ad5mTRAIL+CpG generates systemic immune responses. (A) Parental Renca cells were injected IR, followed
by administration of the indicated therapies IR on d 7. Spleens were excised and live cells counted on d 12. Mean live splenocyte counts from 1
experiment, representative of 4, are shown (n=4 mice per group). For PBS vs Ad5mTRAIL p=0.17; for PBS vs CpG p=,0.001; for Ad5mTRAIL+CpG vs
Ad5mTRAIL p=0.06; for Ad5mTRAIL+CpG vs CpG p=0.16. (B–D) Flow cytometric analyses of spleens are shown; numbers indicate the percentages of
live splenic B cells (B), CD4 and CD8 T cells (C) or CD11c
high DC (D) (* indicates p,0.05 versus PBS controls).
doi:10.1371/journal.pone.0031085.g004
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frequency, compared to PBS-treated mice, was the CD11c
high
splenic DC compartment (Fig. 4D and data not shown).
CpG1826 can activate B cells [13,14], and although we did not
detect a specific expansion in the B cell compartment, we
examined the possibility that Ad5mTRAIL+CpG treatment
induced a humoral immune response. Mice were bled on d 12
after tumor challenge, and serum IgG levels were tested by ELISA.
At this timepoint, Ad5mTRAIL+CpG-treated mice showed
statistical increases in serum IgG relative to control tumor-free
mice (p=0.048), whereas CpG-treated mice did not (p=0.07;
Fig. 5A). CpG treatment did increase serum IgG relative to mice
that received Ad5mTRAIL alone (p=0.03). An examination of
total serum IgG at d 20 revealed an even more pronounced
augmentation in Ad5mTRAIL+CpG-treated mice (data not
shown). Adenovirus-mediated gene therapy leads to the formation
of anti-adenovirus Ab [27], so we also examined the serum
obtained on d 12 and d 20 after tumor challenge for the presence
of anti-adenovirus IgG. Administration of Ad5mTRAIL+CpG led
to a striking increase in serum anti-adenovirus IgG, which resulted
in an approximately 8-fold elevation at d 12, and an approxi-
mately 11,000-fold elevation at d 20, relative to PBS-treated
control mice (data not shown).
Previously, two reports had indicated that tumor challenge of
mice leads to the formation of anti-dsDNA Ab, some of which can
have tumoricidal effects in vitro and in vivo [38,39]. To determine
the extent of anti-dsDNA Ab production after Ad5mTRAIL+CpG
administration for IR Renca tumor challenge, we measured the
amount of anti-dsDNA Ab in the serum by ELISA. At d 12 the
amount of anti-dsDNA Ab present in serum was low; however, the
relative amounts increased by d 20 then declined by d 48 (Fig. 5B).
Thus, administration of Ad5mTRAIL+CpG after IR Renca
Figure 5. Ad5mTRAIL+CpG induces humoral immunity without autoimmunity. (A) Total serum IgG concentrations obtained on d 12 from
the indicated treatment groups. Only Ad5mTR+CpC resulted in a significant increase in serum IgG versus tumor-free control mice. (B) Anti-dsDNA
serum concentrations obtained on d 12, 20, and 48 from Ad5mTR+CpG-treated mice. (For both A and B, * indicates p, 0.05; ** indicates p,0.01). (C, D)
Representative photomicrographs of H&E stained sections of the contralateral kidney (C) and liver (D) taken from one Ad5mTR+CpG-treated mouse
(of a total of 7 analyzed) at d 102 after IR tumor challenge. Scale bar indicates 200 mm.
doi:10.1371/journal.pone.0031085.g005
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increases in serum IgG, which is composed of both anti-adenoviral
and anti-dsDNA Ab.
Given the presence of increased amounts of circulating Ab in
Ad5mTRAIL+CpG-treated mice, it was possible that immune
complex formation/deposition could lead to subsequent autoim-
munity. To explore this possibility, we challenged mice with
parental Renca, and administered Ad5mTRAIL+CpG on d 7. As
this was the only treatment group that had shown a significant
increase in total serum IgG levels, the other treatment groups were
not examined. At d 102, livers, contralateral kidneys, and tumor-
challenged kidneys from surviving mice (n=7) were examined for
pathological evidence of autoimmunity. Importantly, there was no
sign of immune-mediated pathology in the contralateral kidneys
and livers (Fig. 5C and D). At this late timepoint, cavitary lesions
surrounded by areas of interstitial lymphocytic inflammation were
present in several of the tumor-challenged kidneys; these changes
were consistent with tumor elimination (data not shown). Thus,
although Ad5mTRAIL+CpG was administered at the site of
primary renal tumor growth, this therapy induced systemic
immune changes marked by splenomegaly and increased serum
IgG that did not lead to autoimmunity.
IR Ad5mTRAIL+CpG immunotherapy stimulates a CD8-
dependent eradication of metastatic RCC
The primary clinical application of immunotherapy for RCC is
in the clearance of metastases, rather than localized tumors. To
evaluate the ability of local (IR) Ad5mTRAIL+CpG administra-
tion to clear metastatic tumor burdens, mice were given an
orthotopic tumor challenge with parental Renca, followed by IR
Ad5mTRAIL+CpG therapy or PBS on d 7. The lungs were
examined by flow cytometry on d 12 to determine the extent to
which Ad5mTRAIL+CpG therapy increased the frequency of
CD4 or CD8 T cells at this site of metastasis. Mice that received
Ad5mTRAIL+CpG showed increased frequencies of both CD4
and CD8 T cells in the lungs (Fig. 6A). In a second set of mice,
manual enumeration of surface lung tumors at d 21 revealed a
significant decrease in the number of tumor nodules present in
mice that received Ad5mTRAIL+CpG compared to PBS-treated
mice (Fig. 6B). We then performed similar experiments using IR
injection of Renca-Luc cells. While it was not possible to measure
individual kidney versus lung tumor burdens in live mice via BLI
for technical reasons, it was possible to determine the total tumor
burden per mouse. Using this technique, we found that
Ad5mTRAIL+CpG treatment led to a marked reduction in
body-wide tumor outgrowth, as compared to PBS treatment, that
was evident within days of administering immunotherapy (Fig. 6C).
Ad5mTRAIL+CpG treatment on d 7 resulted in a Luciferase
signal at d 21 that was no higher than that observed in tumor-free
mice (p=0.078), indicating that the total body tumor burden had
been reduced to the background level of detection at this time
point (Fig. 6C). Pooled data from multiple experiments produced a
similar result at d 23 (Ad5mTRAIL+CpG vs tumor-free control
mice, p=0.14) (Fig. 6D). Moreover, neither CpG alone,
Ad5mTRAIL alone, nor a control adenovirus were able to bring
about a significant reduction in body-wide tumor outgrowth
(Fig. 6D). Thus, optimal tumor regression required both
Ad5mTRAIL and CpG, and was not due to non-specific effects
of IR adenovirus administration. As before, we then determined
the extent to which CD4 and/or CD8 T cells were required for
this protective effect by depleting mice of these cell populations
prior to administration of Ad5mTRAIL+CpG. Similar to what
was observed for primary renal tumor regression, we found that
mice lacking CD8 T cells were unable to control metastatic RCC
tumor outgrowth following Ad5mTRAIL+CpG therapy, resulting
in large tumor burdens similar to those seen in PBS-treated mice
(Fig. 6D). Depletion of CD4 T cells had an intermediate effect that
was not significant.
Finally, we determined the extent to which IR Ad5-
mTRAIL+CpG administration resulted in a long-term survival
advantage for mice with primary and metastatic renal tumors.
Parental Renca cells were injected IR, and Ad5mTRAIL+CpG or
PBS was given locally on d 7. Therapeutic intervention led to a
significant survival benefit that was evident through d 72 (Fig. 6E).
In a separate experiment, we challenged mice IR with Renca-Luc,
treated on d 7 with Ad5mTRAIL+CpG, and examined mice for
signs of tumor re-growth through d 102. Here, 11 of 15 mice
survived to d 102, and of these only three showed signs of tumor
recurrence by BLI, with 8 remaining tumor-free (Fig. 6F). Thus,
local administration of Ad5mTRAIL+CpG at the primary renal
tumor site induces protective anti-tumor immunity that leads to
the systemic eradication of disseminated tumors in a murine model
of metastatic RCC.
Discussion
The clinical management of RCC is highly variable, and
depends on tumor staging at the time of diagnosis. For localized
renal tumors with no evidence of metastases or with a single
metastasis, radical nephrectomy with surgical resection of the
metastatic lesion is the standard therapeutic approach, and 5-year
survival rates for these patients are high [40]. However, nearly
30% of patients have multiple metastases at diagnosis, and an
equal percentage will develop metastatic tumor recurrence
following nephrectomy. Metastatic RCC is largely thought of as
an incurable disease, with a median survival time of only 18
months [1]. Administration of multikinase inhibitors such as
sunitinib and sorafenib, or antibodies against vascular endothelial
growth factor (VEGF) receptors are largely palliative options, since
complete remissions in response to these agents are rare [41]. In a
small subset of patients the combination of radical nephrectomy
plus high-dose IL-2 can be curative, but this approach is
contraindicated in most individuals due to the severe toxicities
associated with IL-2 administration [3,4,5]. Shortcomings in
current therapeutic options provide the rationale for continued
attempts to identify novel treatment options for patients with
metastatic RCC. At the same time, durable responses to IL-2
therapy illustrate that immunotherapy can be effective, and
suggest that less-toxic immunotherapies, given either with or
without radical nephrectomy, could be beneficial for a greater
number of patients.
In our current study, we used a single IR administration of
Ad5mTRAIL+CpG to induce protective T cell immunity against
metastatic RCC. Of note, the adenoviral vector we used is
replication-deficient and encodes a membrane-bound form of
murine TRAIL. Consequently, we expected only limited direct
killing of tumor cells within the kidney due to the lack of
dissemination of the vector-derived TRAIL protein or the vector
itself via replicative spread. Despite these limitations, IR
Ad5mTRAIL+CpG injection gave rise to systemic T cell responses
that were needed to fully suppress local and metastatic tumor
outgrowth, as well as a humoral immune response characterized
by elevated total serum IgG, anti-adenovirus IgG, and anti-
dsDNA Ab. To our knowledge, this is the first time that local
administration of adenoviral-encoded TRAIL has been shown to
elicit systemic immune responses in an orthotopic, spontaneously
metastasizing tumor model. Other reports investigating the
efficacy of TRAIL-based therapies against localized or metastatic
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PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e31085Figure 6. IR administration of Ad5mTRAIL+CpG stimulates CD8-dependent eradication of metastatic Renca tumors. (A) Parental
Renca cells were given IR, followed by administration of PBS or Ad5mTR+CpG IR on d 7. Flow cytometric analyses examining T cell infiltration were
performed on excised lungs on d 12. Numbers indicate the frequencies of live cells within the gated regions. (B) Mice were challenged as in (A),
followed by PBS or Ad5mTR+CpG on d 7. Lungs were excised on d 21, and surface lung nodules were enumerated as in Figure 2 (n=15 mice per
group, combined from 3 independent experiments). (C, D) Renca-LUC cells were given IR, followed by administration of PBS or Ad5mTR+CpG IR on d
7. (C) Mean total light flux values from 5 mice per indicated treatment group are shown from d 6–21. The mean light flux value for 5 tumor-free mice
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the direct tumoricial activity of the therapy when administered
locally or systemically (such as i.v. injection of agonistic TRAIL
antibodies [20]). It is important to keep in mind that there are
strengths and weaknesses to all experimental tumor models used
depending on the specific question(s) being asked; we were
particularly interested in evaluating the contributions of the
systemic antitumor immune response induced subsequent to
Ad5mTRAIL+CpG administration to the overall control of the
tumor burden.
As both Ad5humanTRAIL and CpG have shown minimal
toxicity as single agents in Phase I clinical trials, they are excellent
candidates for antitumor immunotherapies [9,15]. We explored
the potential of Ad5mTRAIL+CpG as a stand-alone therapy
when the primary renal tumors were still quite small, but tumors
cells had already spread to the lungs (Fig. 2E). It was important to
demonstrate that tumor metastasis to the lung had occurred at the
time of therapy, to eliminate concern that any decrease in lung
tumor burden was due to prevention of metastasis, rather than
clearance of developing lung metastases. However, in a clinical
context, it is tempting to speculate that AdTRAIL+CpG could also
be used as an adjunct therapy prior to nephrectomy in cases of
advanced RCC. Thus, future studies examining the combination
of surgery plus immunotherapy for treatment of larger tumors are
warranted. Use of Ad5mTRAIL+CpG as an adjunct therapy to
nephrectomy would require careful examination of the timing
between immunotherapy administration and surgery, as TRAIL-
induced apoptosis of tumor cells, apoptotic body uptake by local
DC, and activation of naive tumor antigen-specific T cells would
need to occur prior to removal of the tumor-bearing kidney.
Although the Renca tumor line has been widely used to model
RCC in mice, other murine kidney cancer cell lines do exist [42].
These less-studied lines may have variable primary growth and/or
metastatic properties that could influence the efficacy of
experimental immunotherapies. Despite this fact, the majority of
studies have used Renca administered either s.c., which only gives
rise to localized tumors, or i.v., which produces experimental
metastases [16,30,31,32,34,43]. Much has been learned from
studies using the s.c. and i.v. tumor challenge routes, but these
models have important limitations. Consequently, use of the
orthotopic Renca model is becoming more common, as this places
primary tumors in the correct anatomical location that will
spontaneously give rise to lung metastases [20,21,22]. As the lung
is one of the primary sites of metastasis in human RCC [23], the
orthotopic Renca model also provides another degree of clinical
relevance that is lacking in other models. In addition, our use of
Luciferase-expressing Renca cells represents an advance in the
pre-clinical modeling of metastatic RCC, as it allowed us to
sensitively and accurately detect tumor cells in the kidneys and
lungs of mice as early as d 7 post-tumor challenge (Fig. 2D and E)
and to quantitate the kinetic differences in total tumor burdens
that occur in the presence and absence of immunotherapy
(Fig. 5C).
The role of TRAIL in Renca tumor clearance has been
investigated in several previous studies [16,30,44], and our current
work complements and builds on these findings. For example, one
study using an agonistic mAb against DR5 induced only minimal
apoptosis of Renca cells in vitro and in vivo after i.v. tumor
challenge, but robust in vivo protection was observed when
combined with the proteasome inhibitor bortezomib [30]. Another
study showed that while TRAIL impaired the growth of Renca
hepatic metastases in vivo, it was not involved in the protective
response against i.v.-induced Renca lung metastases [44]. Our
data shows that administration of Ad5mTRAIL+CpG at the
primary tumor site not only reduces the primary tumor burden,
but also protects against the outgrowth of metastatic lung tumors
(Fig. 5D and E). The difference between our finding and the
previous reports may stem from the fact that the tumor challenge
and treatment routes were different, leading to qualitatively
different responses.
We showed previously that Ad5mTRAIL can bring about
apoptotic cell death in Renca cells in vitro [45], and demonstrated
the ability of Ad5mTRAIL+CpG to clear localized s.c. Renca
tumors [16]. In the latter study, we found that depletion of CD4 T
cells had a protective effect in mice that received Ad5-
mTRAIL+CpG, leading to prolonged survival relative to intact
mice that received the same therapy. This finding suggested that
regulatory CD4 T cells were suppressing CD8 T cell-mediated
tumor clearance. In contrast, we now find that in mice with
orthotopic Renca tumors, depletion of CD4 T cells in Ad5-
mTRAIL+CpG-treated mice results in larger tumor burdens
(Fig. 3 and 5), indicating that CD4 T cells are directly contributing
to tumor clearance and/or providing the necessary help to
generate an optimal CD8 T cell response. These disparate findings
imply that orthotopic tumor challenge and IR therapy adminis-
tration give rise to fundamentally different tumor microenviron-
ments and immune responses than what occur with standard s.c.
tumor challenges.
In addition to being given as a therapeutic agent, TRAIL can be
used by endogenous T cells as an effector mechanism to bring
about tumor cell death. It was shown previously by Seki et al. that
cytotoxic T lymphocytes did not use TRAIL or perforin to kill
Renca tumor cells, but instead relied primarily upon FasL in vivo
[34], particularly when the cognate antigen levels were low
(determined with HA-expressing Renca-HA cells [46]). A
preliminary assessment of cytolytic mechanisms in our system
supported these findings, in that Ad5mTRAIL+CpG-mediated
renal tumor clearance proceeded normally in mice that were
lacking either TRAIL or perforin (data not shown).
Our current study demonstrates the feasibility of using T cell
stimulation as a means to protect against primary renal and
metastatic tumors in mice. Despite the fact that T cell-mediated
eradication of advanced RCC has been documented in cancer
patients, this is still a rare event [17,18,19]. RCC is an
immunogenic tumor, yet most patients with advanced disease fail
to respond objectively to immunotherapy. One explanation might
be the inability of activated T cells to overcome tumor-derived
immune suppression. Several reports have shown that the
accumulation of tumor-induced suppressor cells, including mye-
loid-derived suppressor cells and regulatory T cells, is an
is shown at d 23 to denote background level of detection. Light flux values for Ad5mTR+CpG-treated mice at d 21 are statistically insignificant to
those from tumor-free mice (p=0.182), suggesting tumor eradication was nearly complete. Ad5mTR+CpG vs PBS at d 21, p=0.032. (D) Mean total
light flux values measured on d 21 for 3–10 mice per group, combined from 2 individual experiments, are shown. Ad5mTR+CpG vs Ad5mTR+CpG
with CD4 depletion p=0.186; Ad5mTR+CpG vs Ad5mTR+CpG with CD8 depletion p=0.015; Ad5mTRAIL+CpG – CD8 vs Ad5mTRAIL+CpG – CD4
p=.037; PBS vs Ad5mTR+CpG with CD8 depletion p=0.573; PBS vs CpG p=0.440. (E) Mice were challenged as in (A), followed by PBS or
Ad5mTR+CpG on d 7. Survival data from 10 mice per group are shown through d 72. (F) Mice were challenged on d 0 with Renca-Luc, treated on d 7
with Ad5mTRAIL+CpG, then re-examined at d 102 by BLI for signs of tumor recurrence. Of 15 tumor-challenged mice, 11 survived to d 102, and 8 of
these showed no evidence of tumor re-growth.
doi:10.1371/journal.pone.0031085.g006
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RCC patients [47,48,49,50] and in murine Renca models
[31,51,52,53]. We applied Ad5mTRAIL+CpG therapy to mice
in which the primary renal tumors were left intact. This
immunotherapy led to a striking reduction in body-wide tumor
burdens through d 21–23 (Fig. 5), but we did observe tumor
regrowth in approximately 50% of mice (Fig. 6E and 6F). It is
possible that combining Ad5mTRAIL+CpG with low-dose
cyclophosphamide or sunitinib to remove suppressive cell
populations would lead to complete tumor eradication in a larger
percentage of mice.
Our data demonstrate that combinatorial immunotherapy
consisting of adenovirus-encoded TRAIL+CpG1826 in an ortho-
topic RCC model in mice was effective in inducing a systemic T
cell response that contributed to reducing local and metastatic
tumors. While a humoral immune response was also evident in
treated mice, our studies were not designed to examine the
contribution of the humoral response to the eventual reduction in
tumor burden. The abrogation of tumor clearance after depletion
of CD8
+ cells would suggest that a protective anti-tumor humoral
response was not present, but formal investigation would need to
be done to confirm this conclusion. Perhaps more importantly, the
transient increases in serum IgG and anti-dsDNA did not lead to
development of autoimmunity, further implying that this immu-
notherapeutic approach has the potential for clinical translation.
Our conclusion is supported by the two prior reports on tumor-
induced anti-dsDNA Ab, in which it was suggested that these
antibodies had tumoricidal functions in vitro and in vivo, and did
not trigger autoimmunity [38,39]. In particular, Ad5TRAIL+CpG
may be a suitable treatment alternative for patients with
inoperable, advanced RCC, in that IR administration of
Ad5TRAIL+CpG may stimulate systemic cellular anti-tumor
immunity that can target any residual primary tumor not directly
killed by TRAIL as well as distal metastases.
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